The Jiangsu Public Resource Trading Platform has released a notification indicating the commencement of price negotiations for provincial stock drugs on April 27. The initiative involves 18 shortage drugs, including pralidoxime, deslanoside, promethazine, and agkistrodon halys snake antivenom, with the participation of 30 manufacturers such as Beijing China Resources Hi-Tech Natural Pharmaceutical Co., Ltd, Chengdu Brilliant Pharmaceutical Co., Ltd, Hunan Kelun Pharmaceutical Co., Ltd, and China Resources Double-crane Pharmaceutical Co., Ltd.
Shanghai Sunshine Medical Procurement All-in-One (SMPA) Releases National Average Prices Notice
On the same day, Shanghai’s SMPA issued a notice regarding the national average prices of some in-shortage drugs for February 2023. The notice advises medical institutions to purchase drugs with reliable quality and appropriate prices based on market supply and demand, ensuring both supply and stable prices.
Jiangsu Province’s Approach to Drug Shortages and Price Increases
Jiangsu province has implemented a strategy that allows affected manufacturers to independently and reasonably price related drugs and participate in online bidding. This approach is designed to significantly address the issues of drug shortages and unreasonable price increases for some commonly used drugs, ensuring the stability of the pharmaceutical market and the accessibility of essential medications for the public.-Fineline Info & Tech
